Cell X Technologies and BioLamina enter collaboration to advance standardization in iPSC-based therapeutics

Cell X Technologies today announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents (Biolaminin) with Cell X's Celligent platform, aiming to reduce variability and enhance reproducibility in advanced therapy manufacturing.

This collaboration underscores the critical role of pairing automation with high-quality, standardized reagents in building scalable, reliable, and GMP-compliant workflows for next-generation therapies. By incorporating BioLamina's full-length, human recombinant laminin-521 and laminin-511 isoforms (both research-use-only and GMP-compatible formulations) into predefined and optimized automated workflows, the partnership seeks to streamline iPSC culture and differentiation while minimizing operator-dependent variability.

"Cell X Technologies is committed to advancing automation in regenerative medicine by ensuring that best-in-class reagents are seamlessly integrated into our automated workflows for process characterization, development and manufacturing," said Lynne Frick, CEO, Cell X Technologies. "Our collaboration with BioLamina reflects a shared vision of reducing variability and increasing successes, especially during the critical transition from research to clinical application."

"Standardization, reproducibility, and physiological relevance are at the core of BioLamina's mission to improve patient outcomes and save lives," said Klaus Langhoff-Roos, CEO, BioLamina. "Partnering with Cell X Technologies enables us to showcase how full-length equals full-function. This, when combined with advanced automation platforms, can drive predictable consistency and scalability for iPSC-based manufacturing."

Using Cell X's walk-away automation and imaging, combined with BioLamina's high-quality reagents, the collaboration highlights the common throughline between these complementary technologies. This combination provides robust, reproducible, and regulator-ready cell therapy processes, enabling reliable therapeutic development and manufacturing across the regenerative medicine landscape.